A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease

Trial Profile

A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs AADvac 1 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Proof of concept
  • Acronyms ADAMANT
  • Sponsors Axon Neuroscience
  • Most Recent Events

    • 28 Aug 2017 Planned End Date changed from 1 Feb 2019 to 1 Jun 2019.
    • 28 Aug 2017 Planned primary completion date changed from 1 Feb 2019 to 1 Jun 2019.
    • 17 Jul 2017 Status changed from recruiting to active, no longer recruiting according to an Axon Neuroscience media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top